Baird analyst Brian Skorney reiterated an Outperform rating and $135 price target on Gilead Sciences (NASDAQ: GILD) following Q4 results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE